We focus on independently developing innovative radiopharmaceuticals and expanding into global markets through strategic licensing partnerships. Our development process includes rigorous preclinical evaluation and early-phase imaging studies, followed by formal clinical trials through IND submissions. In addition, we actively introduce promising new radiopharmaceuticals and lead regulatory filings in Taiwan, including the planning, execution, and oversight of late-stage clinical programs to ensure successful market approval.
We are constantly seeking innovative pharmaceutical partnerships that seamlessly combine your expertise with our cutting-edge radioisotope platform technology. Together, we aim to develop the next generation of diagnostic and therapeutic drugs to combat serious and hard-to-treat cancers.
